Vir Biotechnology (VIR) Long-Term Investments (2018 - 2026)

Vir Biotechnology has reported Long-Term Investments for 9 years, with the latest figure at $333.0 million in Q1 2026.

• Quarterly Long-Term Investments rose 52.64% year-over-year to $333.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $333.0 million (up 52.64% YoY) and the FY2025 annual result came in at $314.6 million, up 65.55% from the prior year.
• Long-Term Investments climbed to $333.0 million in Q1 2026 per VIR's latest filing, from $314.6 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $359.7 million in Q1 2024 and troughed at $23.9 million in Q4 2022.
• A 5-year average of $180.2 million and a median of $190.0 million in 2024 frame the typical range for Long-Term Investments.
• The widest YoY moves for Long-Term Investments: up 1612.02% in 2022, down 88.12% in 2022.
• Over 5 years, Long-Term Investments stood at $23.9 million in 2022, then jumped by 339.98% to $105.3 million in 2023, then surged by 80.49% to $190.0 million in 2024, then jumped by 65.55% to $314.6 million in 2025, then advanced by 5.85% to $333.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $333.0 million, $314.6 million, and $304.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.